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Summary 343/350 
Background. Since people with mental illness more likely die from cancer, we assessed whether people with 
mental illness undergo less cancer screening versus the general population.   
Methods. Systematic review and meta-analysis of observational studies. Primary outcome was Odds Ratio 
(OR) of cancer screening in people with mental illness versus the general population. Secondary outcome 
was prevalence of cancer screening in mental illness. Sensitivity and subgroup analyses considered specific 
mental illness, diagnostic criteria, confounder adjustment, country/region, and program vs. opportunistic 
screening. Newcastle-Ottawa Scale was used to assess study quality. This study is registered with 
PROSPERO, number CRD42018114781.  
Findings. Forty-seven publications provided data from 46 samples including 4,717,839 subjects 
(female=69.85%), for screening for breast (k=35, mental illness=296,699, general population =1,023,288), 
cervical (k=29, mental illness=295,688, general population =3,540,408), colorectal (k=12, mental 
illness=153,283, general population =2,228,966), lung (k=1, mental illness=420, general population =0), 
gastric (k=1, mental illness=420, general population =0), ovarian (k=1, mental illness=37, general population 
=0) and prostate (k=6, mental illness=52,803, general population =2,038,916) cancer. Median quality of the 
included studies was high (7; IQR=2). 
Considering any mental illness, screening was significantly lower versus general population for any (k=37, 
OR=0.757,95%CI=0.722-0.792), breast (k=27,OR=0.652,95%CI=0.603-0.705), cervical 
(k=23,OR=0.891,95%CI=0.840-0.945), and prostate (k=4,OR=0.777,95%CI=0.701-0.862) cancer, but not 
for colorectal cancer (k=8,OR=1.02,95%CI=0.903-1.151). In schizophrenia, screening was lower versus 
general population for any, breast, and cervical cancer. In mood disorders, screening was lower versus 
general population for any and breast cancer, without differences for cervical cancer, while screening was 
more frequent for colorectal cancer. 
In any mental illness, screening prevalence of any, breast, cervical, colorectal, and prostate cancer were 
56.5%(95%CI=51.5-61.3%), 61.9%(95%CI=54.7-68.6%), 59.7%(95%CI=49.4-69.2%), 
37.1%(95%CI=28.9-46.1%), and 48.2%(95%CI=31.3-65.5%), respectively.  
Interpretation. Despite the increased mortality from cancer in mental illness, this population receives 
inferior cancer screening versus the general population. Specific approaches should be developed to assist 
people with mental illness to undergo appropriate cancer screening, especially women with schizophrenia.  
Funding. None. 
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Research in context 
Evidence before this study  
People with mental illness have increased cancer mortality than the general population, which is not 
explained by differences in cancer risk alone. One potential explanation is inferior medical care, especially 
low rates of cancer screening, which may lead to a later stage cancer diagnosis. We searched PubMed and 
PsycInfo from database inception up to May 5th, 2019, using the search “(schizophrenia or schizoaffective or 
psychos* or depress* or bipolar disorder or mania or eating disorder or anorexia nervosa or bulimia nervosa 
or binge eating disorder or obsessive or compulsive or post-traumatic stress disorder or anxiety disorder or 
panic disorder) AND (malignancy OR melanoma OR cancer) AND (screening)”. We also hand-searched the 
reference lists of included studies and previous reviews. We included all published observational studies 
reporting prevalence rates of cancer screening in subjects suffering from mental illness. To date, individual 
published studies have provided inconsistent results whether there exists an increase, a decrease, or no 
difference in cancer screening in subjects with mental illness versus the general population. No previous 
meta-analysis has pooled data on frequencies of any and specific types of cancer screening across all mental 
illnesses to provide a comprehensive picture of whether and to what degree a disparity exists between 
subjects with mental illness and the general population. 
Added value of this study 
This study is the first comprehensive evidence-synthesis to date and provides a quantitative estimate of 
disparities in cancer screening in people with multiple mental illnesses vs. the general population. Cancer 
screening is a key component for decreasing cancer mortality. Given that elevated cancer mortality 
contributes to the 20-year premature mortality among people with mental illness, whether there exists a gap 
in cancer screening that could represent a modifiable factor is a clinically relevant question. 
The present study provides concerning evidence based on data from over 4.5 million people, from all 
continents except Africa, showing that subjects (women in particular) experiencing mental illness 
(schizophrenia in particular) undergo less cancer screening than the general population, after accounting for 
several confounding factors. Our subgroup analyses shed further light on the specifics of these disparities, 
showing that disparities occur across countries, but that the extent of such disparities between countries may 
be different, and that they are particularly pronounced for women with schizophrenia. However, even 
subjects with mood disorders, conditions that are far more frequent than schizophrenia, suffer from 
significant cancer screening disparities. Also, we show that the gap is largest where the healthcare has 
improved the most for the general population, namely in program vs. opportunistic cancer screening. Finally, 
we show that Asia is the region where the lowest portion of subjects with mental illness undergoes cancer 
screening, and conversely that Australia is the region where the healthcare system works the best in 
involving subjects with mental illness in cancer screening. 
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Implications of all the available evidence   
The evidence synthesis provided by this study illustrates consistently inferior cancer screening across mental 
disorders, which calls for urgent actions to promote cancer screening in subjects suffering from mental 
illness, and in women in particular, in virtually all regions around the world. Cancer screening programs that 
have shown to be effective in the general population do not appear to work for as well for people with mental 
illness, and specific as well as tailored interventions are urgently needed. Primary care and prevention 
service stakeholders, general practitioners, and psychiatrists should fill this gap in health system 
organizations and everyday clinical practice. Future, large-scale, multi-center prospective studies should 
identify what interventions and care structures are most effective and cost-efficient for providing adequate 
cancer screening to people with mental illness, and investigate how this may improve overall health 
outcomes and life expectancy among this vulnerable population.  
Introduction 
People with mental illness die around 15-20 years earlier than the general population, primarily due to 
physical health conditions (1-3). The disparities in physical health between those with mental illness and the 
general population is increasing over time, and those with mental illness are seemingly not benefitting from 
the improvements in health outcomes seen in the general population (1). Cardiovascular diseases are the 
most common cause of death with a two- to three-fold increase in standardized mortality ratios (4, 5), 
together with several frequent comorbidities, such as osteoporosis, metabolic syndrome and diabetes (6-8).  
In addition to the aforementioned comorbid conditions, cancer is also responsible for increased mortality in 
mental illness. While the overall incidence of cancer in mental illness is similar to the general population (9), 
mortality from cancer in both genders is increased 1.4- to 2- fold (4). The incidence of cervical cancer has 
been reported as slightly less than that in the general population (10) but mortality rates are higher, with a 
high case fatality ratio for women with cervical (1.98, 95% confidence interval [CI] 1.31-2.92) or breast 
cancer (1.23, 95% CI 1.01-1.51) and an overall cancer mortality rate ratio in women with mental illness of 
1.24 (95% CI 1.17-1.32) (11). Original studies have also described increased mortality in colorectal cancer 
(12).  
Several reasons could explain why cancer mortality differs between subjects with and without mental illness. 
For instance, increased cancer mortality in mental illness may be due to disparities in care (13), in that 
people with mental illness are significantly less likely to receive surgical interventions or radiotherapy and to 
have fewer chemotherapy sessions (10). Additionally, it has been suggested that those with mental illness 
may be less tolerant of intensive treatment regimens with significant side effect burdens and also that co-
morbid physical illness may contribute to the increased mortality rates (14). Another potential explanation, 
however, is that increased cancer mortality in mental illness may be due to delayed cancer diagnosis (i.e., 
detection at an advanced stage when the prognosis is already poor) (15).  
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Despite the fact that  few studies have questioned a delayed cancer diagnosis in mental illness(16), others 
have shown that later stage at diagnosis, including presentation with metastases, is one of the main factors 
explaining increased cancer mortality in subjects with mental illness compared with non-users of mental 
health services.(10, 12) Also, previous systematic reviews have suggested that the quality of all preventive 
services for those with mental illnessis of lower quality (17). Additionally, both narrative reviews and meta-
analyses in women with mental illness have shown substantial disparities in cancer screening compared to 
the general population (18, 19), although only examining female samples, specifically with relation to breast 
cancer. Thus, there is currently little understanding of the extent to which these disparities persist across 
sexes and cancer types. Furthermore, the differences in cancer screening between diagnostic categories of 
mental illness, and across nations, regions and related health care systems, deserve further exploration.  
Therefore, in order to provide an updated understanding of how disparities in cancer screening may affect 
people with mental illness, we conducted a systematic review and meta-analysis investigating screening rates 
across all cancers in subjects with mental illness. We further sought to conduct subgroup analyses to examine 
differences with regards to cancer screening types, sex, region, and psychiatric diagnoses. We hypothesized 
that subjects with mental illness would be disadvantaged in cancer screening compared with the general 
population, that such disparities are most pronounced in people with schizophrenia, but also in patients with 
mood disorders. Furthermore, we hypothesized that cancer disparities would be relatively universal across all 
types of cancer, and across all regions.  
Methods 
Search, inclusion criteria 
We followed an a-priori protocol registered in PROSPERO, CRD42018114781. We complied with the 
procedures outlined by the 2015 update of the Preferred Reporting Items for Systematic review and Meta-
Analysis Protocols (PRISMA-P) (http://www.prisma-statement.org/) (20) and the Meta-analysis Of 
Observational Studies in Epidemiology (MOOSE) guidelines (21), performing an electronic literature search 
from database inception and without language restriction on May 5th, 2019, using PubMed and PsycInfo. 
The following search key was used in PubMed, with equivalent/appropriate syntax for PsycInfo 
“((schizophrenia or schizoaffective or psychos* or depress* or bipolar disorder or mania or eating disorder or 
anorexia nervosa or bulimia nervosa or binge eating disorder or obsessive or compulsive or post-traumatic 
stress disorder or anxiety disorder or panic disorder) and (melanoma or malignancy or cancer) and 
(screening)”. In addition to systematic database searches, references of previous reviews on this topic and of 
included studies were hand-searched for potential additional eligible studies. 
Inclusion criteria were: i) observational studies, ii) focusing on any type of cancer screening, iii) in patients 
with mental illness, defined according to structured criteria, validated scale, or clinical records, and iv) which 
reported prevalence of cancer screening in patients, or comparative measures between patients and the 
general population. No restriction was applied to mental illness or cancer type.  
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Couples of two authors (EF, MF, ED, JF, AK, AM, BS, JS) independently conducted the search and selected 
eligible papers. Any disagreement was resolved by consensus by a third author (MS). 
Data extraction 
The following information was extracted into a pre-defined excel spreadsheet. Author, year, diagnostic 
criteria, specific mental illness, age range of the population, number of patients, number of controls, total 
population, country, type of cancer participants were screened for, percent females, whether association 
measures were adjusted or not, which variables the association measures were adjusted for, the percentage or 
raw number of subjects receiving cancer screening in patients and in controls, and - if available - adjusted 
association measures quantifying eventual disparities in cancer screening between mental illness patients and 
controls (OR, RR, together with 95% confidence intervals). Two authors (MS, EF) independently extracted 
data. Any disagreement was resolved by consensus. No language restriction was applied. 
Quality assessment 
Two authors (MS, ED) independently assessed the quality of the included studies with the Newcastle-Ottawa 
Scale (NOS), with a score >7 (out of 9) indicating high quality (22). 
 Meta-analysis 
Given that we anticipated considerable heterogeneity across included studies, we performed a random-effects 
meta-analysis (23, 24) using comprehensive meta-analysis (CMA, version 2). We calculated the odds ratio 
(OR) and 95% CI of any and specific cancer screening in patients with mental illness versus the general 
population (primary outcome), and the pooled prevalence of cancer screening in patients together with its 
95%CI (secondary outcome). Heterogeneity was assessed with the I2 statistics for each analysis (with 
significant heterogeneity being indicated by I2≥50% (25). Publication bias was assessed via visual inspection 
of funnel plots and the Begg-Mazumdar Kendall's tau and Egger bias test (26). We also calculated the trim 
and fill adjusted analysis (27) in case of publication bias (namely Egger’s test p-value <0.1), and the fail-safe 
number (estimated number of studies needed to move the effect size from significant to non-significant).  
We also ran sensitivity analyses considering only studies, which defined mental illness according to any 
version of the DSM or ICD-criteria, and in studies adjusting for confounding factors. 
Also, we ran subgroup analyses comparing cancer screening disparities and prevalence in patients with 
schizophrenia versus patients with mood disorders, comparing studies from different regions, and comparing 
cancer screening usually implemented in the context of screening programs, based on the available 
quantitative evidence (breast and cervical) vs. other/opportunistic cancer screening (colon, prostate). Given 
the different health care system between Canada and United States of America (national health service 
versus. insurance-based service), we did not pool the two countries together in the “North America” region, 
but analyzed them separately instead. 
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Finally, we run random effect meta-regression to test whether and quantify how the gap between subjects 
with mental illness and the general population increased with increasing screening rates in the general 
population. 
Results 
Search results and the study selection process are described in Figure 1. Out of 3,710 initial hits, we screened 
3,004 studies at the title/abstract level, selecting 145 studies for full-text assessment. We excluded 98 studies 
for specific reasons after full-text assessment, and finally included data from 46 samples (reported in 47 
publications). The complete list of the 98 studies excluded after full-text assessment, with reasons for 
exclusion, is reported in Supplementary material, page 17. 
Detailed characteristics and references of included studies are reported in Supplementary material, page 2. 
Overall, this meta-analysis reports data from 4,717,839 subjects (501,559 patients with mental illness, and 
4,216,280 controls), who were more than two-thirds female (69.85%). Mental illness was defined in 20 
studies according to DSM or ICD diagnostic criteria, 13 with validated scales, 10 according to clinical 
records, and 3 using different criteria within the same study. The cancer screening period lasted from 1 year 
(7 studies) to lifetime screening (6 studies). Age ranged from 18-79 years. Concerning mental illness, 14 
studies focused on subjects with depression only, 6 with schizophrenia, 14 with mixed mental disorders 
while reporting screening estimates for specific groups, and 12 included mixed mental disorders without 
reporting on specific diagnostic groups. All continents except Africa were represented. Specifically, 25 
studies were conducted in the USA, 5 in Canada, 3 in the UK, 3 in Australia, 2 in Israel, 2 in Denmark, and 
one each in Taiwan, Hong Kong, in the  European Union (without specifying countries), in Sweden,  Japan, 
and in the USA plus Canada. Overall, 31 studies provided adjusted estimates, while 15 did not consider the 
influence of confounding factors. Confounding factors considered in the analyses heterogeneously included 
social, economic, demographic, behavioral, and clinical factors potentially influencing the association 
between mental illness and low cancer screening. A detailed report on the quality of included studies 
according to the NOS scale is reported in Supplementary material, page 13. The quality of included studies 
was high (NOS score >7) in 26 out of 46 (56.52%) studies, with a median=7 (IQR = 2). 
Results of main comparative random-effects meta-analysis together with publication bias, fail-safe number 
and trim and fill analysis are reported in detail in Table 1. A forest plot is also represented in Figure 2, 
showing disparities in cancer screening between mental illness and the general population in any, breast, 
cervical and colorectal cancer. 
Screening occurred in significantly fewer people with mental illness than in controls for any (k=37, OR = 
0.76, 95%CI 0.72-0.79, p<0.001), breast (k=27, OR = 0.65, 95%CI 0.60-0.70, p<0.001), cervical (k=23, OR 
= 0.89, 95%CI 0.84-0.94, p<0.001),  and prostate cancer (k=4, OR = 0.78, 95%CI 0.70-0.86, p<0.001), but 
not for colorectal cancer. In schizophrenia, screening was significantly less likely than controls for any, 
breast, and cervical cancer. In mood disorders, screening was significantly less likely than in controls for any 
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and breast cancer, without any difference for cervical cancer, while screening was more frequent than in 
controls for colorectal cancer. 
Publication bias emerged only for any cancer screening in any mental illness (one out of 12 comparisons, 
with fail-safe N equal to 3,117). The trim and fill analysis confirmed that subjects with any mental illness are 
significantly less likely to receive any cancer screening even when adjusting for indicated publication bias.  
Results of comparative sensitivity random-effects meta-analysis together with publication bias, fail-safe 
number, and trim and fill analyses are reported in detail in Table 1 (together with main analyses).  
Considering studies using DSM/ICD criteria, compared with the general population, any cancer screening 
was significantly less likely in any mental illness and in schizophrenia, but not in mood disorders. In patients 
with any mental illness, schizophrenia, and mood disorders, breast cancer screening rates were the lowest 
versus the control group compared to all other examined cancers.  Prostate cancer screening was also 
significantly less likely in any mental illness compared with the general population. Conversely, cervical 
cancer screening rates were not different from the general population in any mental illness, schizophrenia, or 
mood disorders. Similarly, colorectal cancer screening rates were not different between any mental illness 
and controls.  
Publication bias emerged in four out of 11 comparisons, and results remained significant after a trim and fill 
analyses.  
 
In studies adjusting for confounding factors, any cancer and breast cancer screening rates were significantly 
lower versus controls in subjects with any mental illness, schizophrenia, and mood disorders. Cervical cancer 
screening was less frequent in any mental illness, and schizophrenia compared with controls, but no 
difference emerged for mood disorders when considering adjusted studies only. Prostate cancer screening 
rates were lower in any mental illness compared with controls in adjusted studies. Finally, in adjusted 
studies, colorectal cancer screening did not differ significantly between subjects with any mental illness, or 
mood disorders, and controls.  
Publication bias emerged in three out of 12 comparisons and results remained significant after a trim and fill 
analyses, with fail-safe numbers ranging from 136 to 7,862 (see Table 1). 
Detailed results of subgroup analyses of country/region, diagnostic spectrum, and program versus 
opportunistic screening, with heterogeneity measures, are reported in Table 2 and Table 3. In regional 
subgroup analyses, considering any mental illness, no significant differences emerged in terms of disparities 
in any site cancer screening. When looking at specific cancer sites, differences across countries emerged for 
breast, cervical, colorectal, and prostate cancer.  However, disparities were confirmed in the vast majority of 
countries. Conversely, any cancer but not site-specific cancer screening disparities differed among regions in 
schizophrenia and mood disorders (See table 2 and table 3). 
 10 
In diagnostic spectrum subgroup analyses, any site and breast cancer screening disparities differed between 
schizophrenia and mood disorders, being consistently lower in schizophrenia. On the other hand, cervical 
screening disparities did not differ between schizophrenia spectrum and mood disorders.  
Finally, disparities in cancer screening were more pronounced in the context of screening programs 
compared with opportunistic screening. 
Detailed results of the prevalence of cancer screening analyses are reported in Table 4. In any mental illness, 
screening prevalence of any site, breast, cervical, colorectal, and prostate cancer were 56.5% (95%CI=51.5-
61.3%), 61.9% (95%CI=54.7-68.6%), 59.7% (95%CI=49.4-69.2%), 37.1% (95%CI=28.9-46.1%), 48.2% 
(95%CI=31.3-65.5%) respectively, and no differences emerged between people with schizophrenia and 
mood disorders. Conversely, large regional differences emerged in cancer screening prevalence for all 
aforementioned cancer sites, with Asia consistently having the lowest prevalence of cancer screening, 
Europe, Canada and USA being overall in the middle, and Australia providing the highest rates of cancer 
screening in subjects with mental illness. 
Results of meta-regression are reported in Table 5. Result show that considering any cancer, cervical cancer, 
and colorectal cancer, the gap between subjects with mental illness and the general population increases with 
increasing participation of the general population in cancer screening (p<0.001 in each group). 
Discussion 
The current meta-analysis is the first investigating any and specific cancer screening rates among people with 
any mental illness, including data from over 4.5 million subjects from all parts of the world, except Africa. 
Results indicate that subjects with mental illness experience disparities in any, breast, cervical and prostate 
cancer screening compared with the general population, particularly for breast cancer and in females with 
schizophrenia. Disparities are also apparent across different regions of the world but to a different extent. 
Given that cancer screening protects from cancer mortality  (70% decline in cervical cancer mortality since 
screening introduction)(28), such disparities may lead to increased cancer mortality in subjects with mental 
illness. 
The results of our meta-analysis extend previous narrative reviews and confirm our hypothesis that subjects 
with mental illness undergo less cancer screening than the general population. Results are in line with 
Aggarwal et al. (studies=19, participants=106,905) (18), Lord et al. (studies=19 in total, 18 for 
mammography, 10 for uterine cance screening, 4 for colonoscopy, participants=1,377,147) (17), and the 
meta-analysis of breast cancer screening (mammography) by Mitchell et al. (studies=24, 
participants=715,705) (19), as well as previous studies, which showed an association between psychotic 
disorder, substance abuse, and utilization of primary/non-psychiatric care.(29) The present data however 
expand aforementioned previous systematic reviews, including any mental illness and any cancer type in one 
quantitative evidence synthesis. The underlying reasons that may explain disparities in cancer screening are 
multiple. First, while many psychiatrists believe that physical examinations should not be performed by other 
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professionals (30), they rarely perform physical examinations themselves, possibly due to a shortage of time 
and equipment, due to challenges associated with agitated or uncooperative patients, and, possibly, due to a 
degree of skill atrophy, especially in more senior psychiatrists (31). Rare physical examination performed by 
psychiatrists may reflect poor attention to physical health. Second, it has been shown that a negative attitude 
of general practitioners towards cancer screening is associated with an almost 20% increased likelihood of 
patients’ not undergoing cancer screening procedures (32). If general practitioners have negative attitudes 
towards mental illness, this may also partly explain our findings. Third, nurses, who have a positive attitude 
towards promoting physical health in subjects with mental illness, have shown to be more ambivalent when 
it comes to cancer screening (33). Such ambivalence may be due to lack of training on physical health 
promotion, and lack of communication between primary and secondary health-care systems (34). Fourth, 
symptoms and impairment in (social) functioning and in cognition may compromise healthcare access and 
utilization. Fifth, the lower cancer screening rates in mental illness may also be explained by common risk 
factors for mental illness, cancer and a reduced likelihood of undergoing cancer screening. Specifically, 
poverty and low socio-economic status (SES) are known risk factors for psychiatric disorders (35), while 
women with lower educational level and lower SES have also been reported to know less about cervical 
cancer and screening (36). Sixth, patients with mental illness may have difficulties in communicating 
somatic symptoms, or could not be interested in doing so due to depressed mood or negative symptoms. 
Seventh, while a call for optimizing the synergy between mental health and primary care has been raised by 
the World Health Organization,(37) and consistently by other authors,(38-40), this strong rationale has only 
insufficiently translated into any actual change in clinical practice yet.  Finally, diagnostic overshadowing, 
namely clinicians’ attributing early somatic symptoms of cancer to underlying mental illness, may also 
explain why patients with mental illness undergo less medical exams (41). 
We also confirmed the hypothesis that subjects with schizophrenia would suffer from more pronounced 
disparities compared to individuals with mood disorders. Such differences may be due to the persistent 
functional impairment, which is more frequently present in schizophrenia (42), as opposed to more frequent, 
yet still often sub-optimal inter-episode improvement of functioning in people with mood disorders (43). 
Thus, impairment in social functioning, which is closely related to (social) cognition in schizophrenia (44), 
may be responsible for less effective memory,  more severe social withdrawal, less medical care help seeking 
behavior, and less social contacts, which each contribute to less participation in cancer screening. 
Nonetheless, we have also shown that any and breast cancer screening is low in people with mood disorders, 
hence raising public health concerns given the high prevalence of mood disorders compared with 
schizophrenia. 
We also confirmed that cancer screening disparities were universal across different geographical regions, yet 
to a different extent. Region-wise subgroup analyses showed that the lowest prevalence of cancer screening 
in subjects with mental illness is found in Asia, and the highest in Australia, with Europe, USA and other 
regions ranging between these two extremes. However, paradoxically, Australia also had the highest 
disparities for some cancer sites, and in people with mood disorders in particular (see table 3). This result can 
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be explained by the fact that disparities are largest where screening in the general population is the highest, 
as shown by the meta-regression analyses. In other words, if in Australia cancer screening campaigns work 
brilliantly for the general population, this does not hold true for patients with mental illness, who do not 
benefit as much from health-care progress as the general population. Differences among regions may also be 
due to variable measurements healthcare system properties, or cohort-level characteristics. 
Despite confirming most of our hypotheses, colorectal cancer screening did not differ between mental illness 
and controls, although the colorectal cancer screening prevalence was the lowest (37.1% versus 48.2%-
61.9% for the other cancer sites). This finding indicates that cancer screening rate disparities also depend on 
the rates of cancer screening in the general population. For instance, when the general population suffers 
from low cancer screening coverage (45-47), disparities for the mentally ill might not be evident due to a 
ceiling effect.   
The present work has several implications, given that cancer screening disparities are highest for those 
cancers where universal programs usually exist around the world (i.e., breast, cervical), compared with other 
cancer sites (i.e., colon), for which opportunistic screening procedures are performed. In other words, while 
cancer screening campaigns work well in preventing cancer in the general population in several countries 
with national screening programmes, such as in the UK, Italy, and Sweden, among others, apparently this 
benefit does not generalize to people with mental illness. For instance, while a meta-analysis from 2001 (48) 
showed that more women who received a reminder letter attended cancer screening (OR=1.64, 95% 
CI=1.49-1.80), and while other strategies seem to promote cancer screening in the general population, (49-
52) approaches generally working with subjects not affected by mental illness might not work for subjects 
with mental illness. Therefore, such interventions should likely involve awareness among mental health 
specialists, and facilitation of communication between primary and tertiary care as well as between 
specialists in mental health and physical health care, aiming for a close collaborations between mental health 
and primary care.(37-40, 53) 
The present work has several limitations. First, results were virtually always heterogeneous, calling for 
cautious interpretations, especially of some of the marginally significant findings. More specifically, the 
studies included in the present meta-analysis reported on studies from countries with different screening 
guidelines and with different follow-up durations. Second, in subgroup analyses, some regions were under-
represented (i.e., Asia versus USA). Hence, results on differences among these under-represented countries 
and others should be considered exploratory. Third, we relied on published data and were only able to report 
results that were adjusted for a limited number of potential confounders, namely those that the authors of the 
original papers had adjusted their analyses for. Furthermore, based on the more limited data, there remains 
controversy about the value of screening for prostate cancer (54). However, prostate cancer screening was 
included in our analyses, as reduced uptake in people with mental illness may serve as a marker of reduced 
access to preventive care in general. By definition, our results only apply to cancer sites for which 
widespread screening exists. Due to very limited data on lung cancer, despite high smoking frequencies in 
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the mentally ill (55, 56), our results cannot explain disparities in survival for lung cancer (or other cancers), 
yet, likely similar barriers to screening and health care access and quality for mental illness will be at play 
there too. Furthermore, since too few studies were available that differentiated between unipolar vs bipolar 
mood disorder, we were unable to conduct subgroup analyses of cancer screening across these two 
subgroups. Additionally, studies adjusting for potentially confounding factors considered heterogeneous 
types and numbers of covariates. Finally, we did not find any studies on melanoma, although screening for 
this cancer is common in several countries, including Australia.  
In conclusion, subjects with mental illness, including mood disorders, and in particular women with 
schizophrenia, undergo cancer screening significantly less frequently compared with the general population. 
Such a gap is most pronounced for those cancers for which the general population often receives universal 
screening based on national programs. Such disparity may contribute to the life expectancy gap between 
subjects with psychiatric disorders and the general population. Asia has the lowest screening rates, and 
Australia has the highest, and disparities seem to be the highest where the general population is best involved 
in cancer screening programs. More studies are needed on lung cancer screening, given the high rates of 
smoking in people with mental illness. Specific strategies, which should ideally involve mental health 
departments, general practitioners, and prevention as well as primary care departments, should be tested and 
implemented in order to fill this important health care gap and to avoid subjects with mental illness being left 
behind in cancer prevention. 
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Figure 2.  
Title. Forest plot with estimates of disparities in cancer screening between subjects with mental illness and 
the general population: main and sensitivity analyses 
Legend. MI, mental illness 
 
Legend. MI, mental illness. 
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Table 1. Comparative random effect meta-analysis of cancer screening (breast, cervical, colorectal, prostate) in patients with mental illness compared with 
general population, and sensitivity analysis on studies using ICD/DSM diagnosis, and adjusted studies. 
Cancer screening Publications/samples OR (95%CI)*  p value I2 Egger’s test p value / Fail safe N / Effect size after trim and fill (in case of publication bias) 
 
Any mental illness# 
 
Any diagnostic criteria 
Any cancer 37/149 0.757 (0.722-0.792) <0.001 98.53% 0.025 /5174 / 0.905 (0.862-0.951) 39 studies trimmed looking for missing studies to right of mean 
Breast 27/85 0.652 (0.603-0.705) <0.001 97.58% 0.878 /7920  
Cervical 23/44 0.891 (0.840-0.945) <0.001 98.47% 0.811 / 2820  
Colorectal 8/11 1.02 (0.903-1.151) 0.753 97.84% 0.463 / NA /  
prostate 4/9 0.777 (0.701-0.862) <0.001 79.68% 0.493 / 457   
DSM or ICD diagnosis 
Any cancer 14/78 0.800 (0.762-0.839) <0.001 97.16% 0.002 / 8808 / 0.948 (0.903-0.996) 20 studies trimmed looking for missing studies to right of mean 
Breast 8/44 0.642 (0.579-0.711) <0.001 96.44% 0.006 / 7798 / 0.674 (0.609-0.745) 4 studies trimmed looking for missing studies to right of mean 
Cervical 9/25 0.959 (0.939-1.055) 0.876 97.61% 0.742 /  NA   
Colorectal 3/5 1.018 (0.869-1.193) 0.821 82.08% 0.481 /  NA   
Prostate 2/4 0.757 (0.653-0.878) <0.001 54.72% 0.042 /   49   / 0.813 (0.687-0.962) 2 studies trimmed looking for missing studies to right of mean 
Adjusted studies* 
Any cancer 31/121 0.763 (0.731-0.797) <0.001 97.82% 0.004 / 7846 / 0.898 (0.861-0.938) 30 studies trimmed looking for missing studies to right of mean 
Breast 21/69 0.674 (0.628-0.724) <0.001 96.18% 0.039 / 4057 / 0.799 (0.743-0.859) 17 studies trimmed looking for missing studies to right of mean 
Cervical 19/35 0.876 (0.821-0.936) <0.001 98.67% 0.111 /  153  
Colorectal 5/7 0.949 (0.889-1.012) 0.111 70.26% 0.530 /   NA  
Prostate 4/9 0.777 (0.701-0.862) <0.001 79.68% 0.494 /  457  
 
Schizophrenia and other non-affective psychoses 
 
Any diagnostic criteria 
Any cancer 13/24 0.624 (0.525-0.742) <0.001 98.78% 0.540 / 4696 
Breast 8/12 0.518 (0.431-0.624) <0.001 91.99% 0.604 / 2232 
Cervical 7/10 0.746 (0.597-0.932) 0.010 98.59% 0.622 /  163  
DSM or ICD diagnosis 
Any cancer 8/14 0.666 (0.539-0.822) <0.001 98.12% 0.280 /  494  
Breast 4/7 0.578 (0.516-0.647) <0.001 26.62% 0.020 /  249  / 0.621 (0.548-0.704) 4 studies trimmed looking for missing studies to right of mean 
Cervical 4/6 0.789 (0.549-1.135) 0.202 99.09% 0.919 /  NA   
Adjusted studies* 
Any cancer 10/15 0.627 (0.521-0.754) <0.001 98.09% 0.160 / 1421   
Breast 5/8 0.601 (0.561-0.644) <0.001 15.58% 0.029 /  517  / 0.617 (0.566-0.672) 4 studies trimmed looking for missing studies to right of mean 
Cervical 5/6 0.690 (0.497-0.958) 0.027 99.10% 0.614 /  136  
 
Mood disorders 
 
Any diagnostic criteria 
Table 2. Region subgroup random effect meta-analysis of cancer screening (breast, cervical, colorectal, prostate) in patients with mental illness # 
Country/region Publications/samples OR (95%CI)*  p value I2 Subgroup difference across different regions p value 
 
Any mental illness 
 
Any cancer 
Israel 2/2 0.807(0.750-0.869) <0.001 39.50% 0.085 
Europe 6/25 0.777(0.728-0.829) <0.001 97.87%  
USA* 21/105 0.769(0.717-0.825) <0.001 98.41%  
Australia 2 / 5 0.762(0.697-0.834) <0.001 94.90%  
Canada* 6/9 0.729(0.587-0.905) 0.004 88.55%  
Asia 1/3 0.302(0.157-0.581) <0.001 NA  
Breast cancer 
Canada* 4/4 0.929(0.523-1.650) 0.8 63.73% 0.016 
Israel 1/1 0.767(0.691-0.851) <0.001 NA  
USA* 18/65 0.667(0.608-0.732) <0.001 97.97%  
Europe 4/12 0.655(0.573-0.749) <0.001 91.82%  
Asia 1/3 0.302(0.157-0.581) <0.001 NA  
Cervical cancer 
USA* 14/24 0.980(0.880-1.092) 0.714 96.98% <0.001 
Europe 3/12 0.880(0.822-0.941) <0.001 97.97%  
Australia 2 / 3 0.728(0.674-0.787) <0.001 8.14%  
Canada* 5/5 0.670(0.491-0.914) 0.012 92.73%  
Colorectal cancer 
Europe 1/1 1.300(1.095-1.543) 0.003 NA <0.001 
USA 6/9 1.011(0.879-1.163) 0.878 98.05%  
Australia 1/1 0.900(0.861-0.941) <0.001 NA  
Prostate cancer 
Israel 1/1 0.830(0.781-0.882) <0.001 NA <0.001 
USA 2/7 0.772(0.638-0.935) 0.008 69.38%  
Australia 1/1 0.720(0.700-0.740) <0.001 NA  
 
Schizophrenia spectrum disorders 
 
Any cancer 
Israel 1 / 1 0.830(0.781-0.882) <0.001 NA <0.001 
Canada 2/6 0.674(0.618-0.735) <0.001 50.26%  
USA 5/13 0.619(0.449-0.852) 0.003 99.16%  
Europe 5/8 0.545(0.409-0.727) <0.001 98.36%  
Breast cancer 
Canada 1 / 1  0.640(0.578-0.708) <0.001 NA 0.090 
Europe 3/4 0.576(0.504-0.659) <0.001 41.03%  
USA 4/7 0.463(0.345-0.623) <0.001 67.29%  
Table 3. Subgroup meta-analysis of disparities in any cancer screening between schizophrenia spectrum disorder and mood disorders, and in program vs 
opportunistic screening 
Mental illness Cancer Publications/samples Odds ratio and p value Heterogeneity Subgroup difference between 
schizophrenia and mood 
disorders p value 
Diagnostic spectrum 
Schizophrenia spectrum 
disorders 
Any cancer 13/24 0.624 (0.525-0.742); p < 0.001 98.78% 0.002 
Mood disorders Any cancer 25/49 0.851 (0.783-0.926); p < 0.001 98.84%  
Schizophrenia spectrum 
disorders 
Breast cancer 8/12 0.518 (0.431-0.624); p < 0.001 91.99% 0.001 
Mood disorders Breast cancer 18/24 0.770 (0.658-0.886); p < 0.001 98.09%  
Schizophrenia spectrum 
disorders 
Cervical cancer 7/10 0.746 (0.597-0.932); p = 0.010 98.59% 0.069 
Mood disorders Cervical cancer 16/19 0.930 (0.856-1.011); p = 0.090 96.84%  
Program vs opportunistic 
Program Breast and cervical cancer 28/131 0.734 (0.698-0.772); p<0.001 98.53% 0.002 
Opportunistic Colon and prostate cancer 2/18 0.905 (0.803-1.019), p=0.1 98.35%  
 
 
 
Table 4. Meta-analysis of prevalence of cancer screening (breast, cervical, colorectal, prostate, gastric, lung, ovarian) in patients with mental illness (defined 
according to any criteria), and subgroup analysis across countries and between schizophrenia and mood disorders. 
Country/region and Mental 
illness 
Cancer Publications/samples Prevalence Heterogeneity Subgroup comparison between 
schizophrenia and mood 
disorders 
Any cancer 
Any mental illness Any cancer 34/155 56.5% (51.5-61.3) 99.91%  
Australia Any cancer 1/2 87.6% (78-93.4) NA <0.001 
Europe Any cancer 6/23 69.5% (64.1-74.4) 99.54%  
Canada Any cancer 3/3 61.7% (43.4-77.2) 99.46%  
USA Any cancer 19/111 58.8% (53.4-64) 99.9%  
Israel Any cancer 2/2 34.4% (19.6-53) 99.74%  
Asia Any cancer 3/14 18% (11.9-26.4) 96.83%  
Mood disorders Any cancer 19/35 50.6% (41.4-59.8) 99.94% 0.408 
Schizophrenia spectrum 
disorders 
Any cancer 16/36 44.5% (33.9-55.6) 99.87%  
Breast cancer 
Any mental illness Breast cancer 25/81 61.9% (54.7-68.6) 99.89%  
Australia Breast cancer 1/1 91.5% (83.2-95.9) NA <0.001 
USA Breast cancer 16/65 65.6% (57.9-72.6) 99.89%  
Europe Breast cancer 3/9 56.9% (50.5-63.1) 96.16%  
Canada Breast cancer 1/1 44.8% (42.3-47.4) NA  
Israel Breast cancer 1/1 43.7% (42.2-45.2) NA  
Asia Breast cancer 1 /4 15.4% (8.7-26) NA  
Mood disorders Breast cancer 13/16 57.9% (41.4-7.28) 99.92% 0.570 
Schizophrenia spectrum 
disorders 
Breast cancer 12/17 52.3% (41.8-62.5) 99.53%  
Cervical cancer 
Any mental illness Cervical cancer 20/42 59.7% (49.4-69.2) 99.94%  
Australia Cervical cancer 1/1 84% (75.5-90) NA <0.001 
Canada Cervical cancer 2/2 69.4% (47.7-84.9) 99.48%  
Europe Cervical cancer 3/12 81.4% (78.1-84.3) 99.62%  
USA Cervical cancer 12/25 47% (38.3-55.9) 99.9%  
Asia Cervical cancer  2/2 19.3% (2.8-66.4) 96.39%  
Mood disorders Cervical cancer 11/12 52.9% (31.1-73.6) 99.97% 0.654 
Schizophrenia spectrum 
disorders 
Cervical cancer 10/14 46.7% (32.8-61.1) 99.74%  
Colorectal cancer 
Any mental illness Colorectal cancer 10/18 37.1% (28.9-46.1) 99.79%  
USA Colorectal cancer 7/12 46.7% (35.8-57.9) 99.86% <0.001 
Europe Colorectal cancer 1/1 27% (15.2-43.3) NA  
Asia Colorectal cancer 2 /5 19.3% (13.1-27.6) 7%  
Mood disorders Colorectal cancer 5/5 34.0% (19.4-52.4) 99.89% 0.525 
Table 5. Meta-regression between the gap in screeing rates between the general population and subjects with mental illness, and the screening rates in the 
general population. 
Cancer Publications/samples Beta 95%CI P value 
Any cancer 35/143 -0.79 -1.18 - -0.39 <0.001 
Breast cancer 26/84 0.35 -0.21 – 0.91 0.223 
Cervical cancer 21/42 -1.46 -2.12 - -0.80 <0.001 
Colorectal cancer 6/9 -0.76 -1.13 - -0.39 <0.001 
Prostate cancer 3/8 -0.51 -1.68 - -0.68 0.404 
 
 
 
 
 
 
 
 
1 
 
 
Disparities in cancer screening in people with mental illness across the world: prevalence 
and comparative meta-analysis versus the general population including 4,717,839 people  
 
Supplementary material content 
 
Supplementary table 1. Characteristics of studies reporting on disparities or prevalence of cancer 
screening in subjects suffering from mental illness 
 
Supplementary table 2. Quality of included studies according to Newcastle-Ottawa Scale.  
 
Supplementary table 3. Excluded studies after full text assessment, with reason. 
 
References 
 
 
 
 
 
 
2 
 
 
Supplementary table 1. Characteristics of studies reporting on disparities or prevalence of cancer screening in subjects suffering from mental illness 
Author 
 
Diagnostic 
criteria 
Screening 
period 
(years) 
Age 
Psychiatric 
disorder 
N 
patients 
N 
controls 
N total Country 
Female 
% 
Cancer 
Screening 
procedure 
Adjusted 
(Y/N) 
which 
variables are 
analyses 
adjusted for 
Association 
measure 
Prevalence 
Abrams, 
2012 (1) ⁠ 
ICD-9 1 41,00 
substance use  
disorder 
 
6122 
 
85375 
105 
681 
USA 100,00% cervical pap smear Y 
age, region, 
comorbidity, 
diagnosis, 
race. 
Y Y 
   46,00 psychosis 4747                  
   42,00 
psychosis and 
substance use 
disorder 
1104  
                
   41,00 
bipolar disorder 
or mania 
3319  
                
   43,00 depression 5014                  
Aggarwal, 
2008 
(2) ⁠⁠⁠ 
CES-D 1 
57(50-
79) 
depressive 
symptoms 
 
12621 
 
67368 79 989 USA 100,00% breast mammography N  Y Y 
             colon colonscopy       
Blackwell, 
2008 
(3) 
Composite 
International 
Diagnostic 
Interview 
2 18 - 69 
major depressive 
episodes 
 
 
496 
 
 
4358 
4 854 USA/Canada 100,00% breast mammography Y 
demographic, 
socio-
economic, 
health staus 
and other 
variables 
Y N 
              cervical pap smear       
Carney, 
2006 
(4) ⁠ 
DSM-IV 5 48,30 mood disorder 
 
 
 
 
 
22512 
 
 
 
 
 
131683 
191 
356 
USA 100,00% breast mammography Y 
age, rural 
location, 
utilization of 
nonmental 
health 
services, and 
severity and 
type of the 
mental 
disorder. 
Y Y 
        
psychotic 
disorders 
525  
                  
        
adjustment 
disorders 
8656  
                  
        anxiety disorders 9340                    
        
low severity 
other mental 
disorder 
2113  
                  
 
 
 
 
 
3 
 
        sexual disorder 3175                    
        sleep disorder 3454                    
        
somatoform 
disorder 
3121  
                  
        
substance 
disorder 
6777  
                  
Chochinov, 
2009 
(5) 
⁠⁠ 
ICD-9 2 50-69 schizophrenia 
 
 
 
 
1448 
 
 
 
 
108792 
110 
240 
Canada 100,00% breast mammography Y 
age, region, 
average 
household 
income, 
continuity of 
care, and 
physical 
comorbid- 
Ities. 
Y Y 
Domino, 
2014 
(6) 
clinical 
records 
3 ≥50 schizophrenia 
 
15636 
 
106555 
188 
531 
USA 66,00% colon colon screening Y 
inpatient 
hospital days 
Y Y 
   ≥45         100,00% breast mammography       
   21-65   
  
    100,00% cervical 
cervical 
screening 
      
   ≥50 depression 66340      66,00% colon colon screening       
   ≥40         100,00% breast mammography       
   21-65   
  
    100,00% cervical 
cervical 
screening 
      
Druss, 2002 
(7) ⁠ 
ICD-9 3 <=65 
psychiatric 
disorder only 
(ICD-9 codes 
290 –302 and 
306 – 
319) 
 
 
3 000 
all 
 
 
4 030 
7 030 USA 100,00% cervical pap smear Y 
demographic, 
health status, 
and 
facility-level 
characteristics. 
Y Y 
  2 50-69         100,00% breast mammography       
  1 >=50         0,00% prostate PSA       
  1 >=50   
 
 
 
    21,00% colon 
fecal occult 
blood 
      
  3 <=65 
substance use 
disorder 
  
    100,00% cervical pap smear       
  2 50-69         100,00% breast mammography       
  1 >=50         0,00% prostate PSA       
  1 >=50   
  
    21,00% colon 
fecal occult 
blood 
      
  3 <=65 
dual diagnosis 
(co- 
morbid 
psychiatric and 
substance use 
disorders). 
 
 
 
    100,00% cervical pap smear       
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  2 50-69         100,00% breast mammography       
  1 >=50         0,00% prostate PSA       
  1 >=50   
  
    21,00% colon 
fecal occult 
blood 
      
Druss, 2008 
(8) 
CIDI-
SF>=3 
(DSM-III) 
1 >50 
major depressive 
disorder 
 
 
 
 
2220 
 
 
 
 
27861 30 081 USA 69,80% colon 
fecal occult 
blood 
Y 
gender, race, 
age, poverty 
status, 
insurance 
coverage and 
number of 
chronic 
medical 
conditions. 
Y N 
   >40       100,00% breast mammography       
   <65       100,00% cervical pap smear       
Eriksson, 
2019(9) 
ICD-10 5 23-60 
Schizophrenia 
spectrum 
disorders 
2364 275879 
341 
171 
Sweden 100% cervical Pap smear Y age Y Y 
    Mood disorders 43832           
    
Phobia, anxiety, 
stress-related 
disorders 
19096  
         
Folsom, 
2002(10) 
 
DSM-IV 1 51,5(≥45) 
schizophrenia or 
schizoaffective 
disorders 
47 NA 
94 USA 47,00% colon 
fecal occult 
blood 
N   N Y 
               100,00% breast mammography        
         
  
    100,00% cervical 
pelvic 
examination 
       
     51,3(≥45) 
major depressive 
disorder 
47  
    47,00% colon 
fecal occult 
blood 
       
               100,00% breast mammography        
         
  
    100,00% cervical 
pelvic 
examination 
       
Fujiwara 
AND 
Inagaki, 
2017, 2018 
(11, 12)  
⁠⁠ 
DSM-5 1 
44,8 (40-
69) 
schizophrenia or 
schizoaffective 
disorders 
 
 
420 
 
 
NA 
420 japan 51,30% colon colon screening N   N Y 
    1 
44,8 (40-
69) 
  
  
    51,10% gastric 
gastric 
screening 
        
    1 
44,8 (40-
69) 
  
  
    51,30% lung lung screening         
    2 
44,8 (40-
69) 
  
  
    100,00% breast mammography         
    2 20-69         100,00% cervical pap smear         
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Gal,2014 
(13) ⁠ 
ICD-10 8 61,00 schizophrenia 
8285 16570 
24 855 Israel 0,00% prostate PSA Y 
sum of PSA 
tests 
Y Y 
Green, 2000 
(14) ⁠ 
SF-36 lifetime 
52,9(18-
102) 
Depression  
 
1173 
 
2299 
3 472 USA 100,00% breast mammography Y 
income, self-
reported 
social-class, 
health status. 
Y N 
            cervical pap smear       
Harder, 
2018 
(15) ⁠ 
ICD-10 2 23-49 Intoxicant abuse 
 
 
3188 
 
 
419552 
466 
419 
Denmark 100% cervical pap smear Y 
age, country 
of origin, 
marital status, 
educational 
level, income 
Y Y 
      
schizophrenia 
and other 
psychoses 
4454  
                  
      
affective 
disorders 
13927  
                  
      
anxiety and 
Obsessive-
compulsive 
disorders 
21641  
                  
      eating disorders 3657                    
Holden, 
2015 (16) 
CES-D na na depression 
37 NA 
37 UK 100% Ovarian na N - N Y 
          colorectal na     
Iezzoni, 
2001 
⁠(17) ⁠ 
NHIS-D 2 >50 
serious mental 
health problem 
 
1944 
 
75818 77 762 USA 100,00% breast mammography Y age Y N 
   
42,4(18-
65) 
 
  
      cervical pap smear       
   >30  
  
      breast 
breast 
examination 
      
Jensen, 2016 
(18) 
clinical 
records 
10 50 - 69 Schizophrenia 1 022 137 692 
144 
264 
Denmark  breast mammography Y 
age, marital 
status, 
ethnicity,  
education, 
psychiatric 
comorbidity 
Y Y 
    
Affective 
disorders 
3 453  
         
    
Anxiety 
disorders 
670  
         
    Substance abuse 1 427           
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Kaida, 2008 
(19) ⁠ 
DSM-IV, 
ICD-10 
3 18-69 depression 
 
 
 
1831 
 
 
 
23521 25 352 Canada 100,00% cervical pap smear Y 
age, 
education, 
income, 
marital status, 
ethnicity, 
healthcare 
utilization 
Y Y 
Katz,2018 
(20) 
clinical 
records 
6 50-74 depression 
 
4354 
 
39964 
44,318 Israeli 100% breast mammography Y 
Socio-
demographic 
factors and 
comorbidities 
Y Y 
Kempe, 
2013 
(21) 
clinical 
records 
2 52-69 depression 
 
9269 
 
38677 47 946 USA 100,00% breast mammography Y 
socioeconomic 
and health 
status variable 
Y Y 
Koroukian, 
2012 
(22) ⁠ 
ICD-9-CM 6 50-64 
mental illness 
and/or 
alcohol/substance 
abuse 
61661 68427 
130 
088 
USA 100,00% breast mammography Y 
comorbid 
conditions and 
length of 
enrollment in 
Medicaid 
Y N 
Kotwal, 
2012(23) 
CES-D, 
HADS, 
PSS-4 
1 57-85 depression 
 
120 
 
1 049 
1 169 USA 0% prostate PSA Y 
Age, ethnicity, 
marital status, 
education, 
income 
Y Y 
    anxiety            
Lasser, 2003 
(24) 
modified 
version of  
PRIME-MD 
2 40-70 anxiety disorders 
 
103 
 
293 672 USA 100,00% breast mammography N   Y Y 
      eating disorders 28                   
      mood disorders 84                   
      PTSD 27                   
      substance abuse 46                   
      somatisation 79                   
      
psychotic 
disorders 
12  
                 
Lindamer, 
2003 
(25) ⁠ 
clinical 
records, 
PANSS, 
HAM-D 
2 
57,6(50-
79) 
schizophrenia 
 
65 
 
51 
116 USA 100,00% breast mammography N   Y Y 
  3            cervical pap smear        
  2 
57,6 (50-
79) 
schizophrenia or 
schizoaffective 
disorders 
  
  100% cervical 
pelvic 
examination 
and pap test 
     
           breast mammography        
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Lindamer, 
2006(26) 
DSM-IV lifetime 
52,9 (44-
72) 
schizophrenia or 
schizoaffective 
disorders 
 
46 
 
NA 46 USA 100,00% breast mammography N   N Y 
Long, 1998 
(27) ⁠ 
clinical 
records 
lifetime 
49,1(41-
50) 
mental health 
treatment, 
hospitalization 
43 62 
105 USA 100,00% breast mammography N   Y Y 
  1 41,70  
  
      breast 
breast 
examination 
       
  1 39,90          cervical pap smear        
Ludman, 
2010 
(28) 
PHQ-9 2 51-65 depression   
 
 
 
755 
 
 
 
3904 
4 659 USA 100,00% breast mammography Y 
age, ethnicity, 
marital status, 
education, 
current 
smoker, 
comorbidity, 
body 
dissatisfaction 
Y Y 
  3 40-65           cervical pap smear     
Martens, 
2009 
(29) ⁠ 
clinical 
records 
3 18-69 schizophrenia 
 
 
3220 
 
 
335294 
338 
514 
Canada 100% cervical pap smear Y 
age, region, 
income, 
continuity of 
care, physical 
comorbidities 
Y Y 
Masterson, 
2010 
(30) 
Kentucky 
2002 
BRFSS 
lifetime ≥40 low depression 
 
 
 
543 
 
 
 
 
2818 5 101 USA 100,00% breast mammography Y 
age, race, 
marital status, 
education, 
income, and 
health 
insurance 
status 
Y N 
    high depression 192                
    
very high 
depression 
307  
              
    low anxiety 622                
    high anxiety 238                
    very high anxiety 381               
Mo, 2014 
(31) ⁠ 
clinical 
records 
lifetime 21-65 
Severe mental 
illness 
591 NA 
591 Hong kong 100,00% cervical pap smear N   N Y 
   >=40         100,00% breast mammography         
   >=40   
  
    100,00% breast 
breast 
examination 
        
   >=50   
  
    54,00% colon 
fecal occult 
blood 
        
   >=50   
  
    54,00% colon 
flexible 
sigmoidoscopy 
        
   >=50         54,00% colon colonscopy         
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   >=50   
  
    54,00% colon 
double contrast 
barium enema 
        
   >=50   
  
    0,00% prostate 
digital rectal 
exam 
        
Olesen, 
2012 
(32) ⁠⁠ 
Goldberg 
anxiety 
scale >7 
2 44-68 anxiety 
 
295 
 
1657 2 095 Australia 100,00% cervical pap smear Y age Y N 
 
Goldberg 
depression 
scale >7 
  depression 
 
143 
 
             
Owen, 2002 
(33) ⁠ 
clinical 
records 
lifetime 46,30 
mood disorders, 
schizophrenia, 
primary anxiety 
disorder, other 
mental disorders 
 
 
100 
 
 
NA 100 Australia 100,00% cervical pap smear N   N Y 
     
  
      breast 
breast 
examination 
       
Patten, 2009 
(34) ⁠ 
CIDI-SF 2 50-69 major depression 
 
 
 
 
 
 
2651 
 
 
 
 
 
 
3631 6 282 Canada 100,00% breast mammography Y 
age, sex, rural 
place of 
residence, 
education 
level, a 
diagnosis 
of 
hypertension, 
other chronic 
conditions, 
income and 
employment 
status 
Y N 
   ≥18        cervical pap smear       
Peytremann-
Bridevaux, 
2008 
(35) ⁠ 
EURO-D>3 10 67,6(≥50) 
depressive 
symptoms 
 
 
 
10335 
 
 
 
5045 
 
15 380 UE 70,50% colorectal 
colonscopy or 
flexible 
sigmoidoscpy 
Y 
age, gender, 
socioeconomic 
status, 
behavioral 
risk, chronic 
disease, 
disability, 
country 
Y N 
  2 67,6(≥50)   
  
    100,00% breast 
breast 
screening 
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Pirraglia, 
2004 
(36) ⁠ 
CES-D_=21 1 42-52 
high depressive 
symptoms 
 
 
 
 
492 
 
 
 
 
2 493 
3 297 USA 100,00% breast mammography Y 
age, 
race/ethnicity, 
health 
insurance, 
medical 
history and 
use, smoking, 
obesity, and 
socioeconomic 
status 
Y N 
             cervical pap smear       
    
moderate 
depressive 
symptoms 
312  
     breast mammography       
             cervical pap smear       
Salsberry, 
2005 
(37) ⁠ 
ICD-9-CM 3 ≥18 
schizophrenic 
disorders 
 
158 
 
NA 669 USA 100,00% cervical pap smear N  N Y 
   ≥40           breast mammography       
   ≥18 
paranoid 
disorders 
72  
      cervical pap smear       
   ≥40           breast mammography       
   ≥18 
affective 
disorders 
379  
      cervical pap smear       
   ≥40           breast mammography       
   ≥18 anxiety disorders 60        cervical pap smear       
   ≥40           breast mammography       
Stecker, 
2007 
(38) ⁠ 
DSM 5 41,40 depression 
 
270 
 
590 860 USA 100,00% breast mammography N   Y Y 
             cervical pap smear        
             colon colonscopy        
Thomas, 
2018 
(39) ⁠ 
DSM-IV-
TR 
1 48-67 anxiety disorders 
 
641 
 
NA 14 651 USA 100% breast mammography N   N Y 
      bipolar disorders 2115                    
      
major depressive 
disorder 
4806  
                  
      
other psychiatric 
disorders 
754  
                  
      schizophrenia 6335                    
Tuesley, 
2018 (40) 
clinical 
records 
7.5 to 11 18-69 
Schizophrenia or 
bipolar disorder 
 
 
41169 
 
 
2017267 2 058 
436 
Australia 50% colorectal 
Fecal occult 
blood 
Y 
Age, gender, 
state, number 
visits with 
general 
practitioner 
per year 
Y N 
 
 
 
 
 
10 
 
     
  
   
Cervical 
 
Pap smear 
 
    
          prostate PSA     
Vigod, 
2011(41) 
 
DSM-IV 2 56,30 
major depressive 
disorder 
 
 
 
 
 
67 
 
 
 
 
 
840 
1 398 Canada 100,00% breast mammography Y 
Age, income 
level, level of 
education, 
geograph- 
ical variability 
(urban/rural), 
body mass 
index, and 
medical 
and 
psychiatric 
comorbidity 
Y N 
 
Kessler 6-
item >8 
 
58(40-
70) 
clinically 
significant 
depressive 
symptoms 
491  
      cervical pap smear       
Werneke, 
2006 
(42) 
ICD-10 3 50-64 
any psychiatric 
condition 
 
 
 
 
 
 
 
1048 
 
 
 
 
 
 
 
53340 54 388 UK 100,00% breast 
breast 
screening 
Y 
mental health 
variable 
including level 
of psychiatric 
care, number 
of inpatient 
episodes and 
detention, 
diagnosis, and 
the total lenght 
of time a 
patient had 
been seen by 
the psychiatric 
service. 
Y Y 
Weitlauf, 
2013 
(43) ⁠ 
ICD-9 5 18-65 PTSD 
 
5668 
 
16828 34 123 USA 100,00% cervical pap smear Y 
age, income, 
physical 
comorbidities 
Y Y 
    depression 11627              
Woodhead, 
2016 
(44) 
ICD-10 3 50-70 schizophrenia 
 
 
406 
 
 
 
132293 
133 
184 
UK 100,00% breast mammography Y 
age, ethnicity, 
deprvation, 
primary-care 
consultation 
frequency 
Y Y 
     25-64           cervical pap smear         
   50-70 
bipolar affective 
disorder 
298  
      breast mammography         
   25-64           cervical pap smear         
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   50-70 
Other non-
organic 
psychoses 
187  
      breast mammography         
   25-64           cervical pap smear         
Xiong, 2008 
(45) ⁠ 
DSM-IV-
TR 
lifetime 40,10 
Severe mental 
illness 
229 NA 
229 USA 100,00% cervical pap smear N   N Y 
   40,10         100,00% breast mammography        
   40,10   
  
    100,00% breast 
breast 
examination 
       
   >50         0,00% prostate PSA        
   >50   
  
    0,00% prostate 
digital rectal 
exam 
      
   >50   
  
    54,00% colorectal 
fecal occult 
blood 
      
   >50   
  
    54,00% colorectal 
flexible 
sigmoidoscopy 
       
Yee, 2011 
(46) 
⁠ 
ICD-9 3 
57,2(50-
65) 
Anxiety, 
depressed mood, 
dissociative 
symptoms, eating 
disorders, 
impulse control 
disorders, manic 
symptoms, 
personality 
disorders, 
psychosis, 
somatoform 
disorders, and 
substance use 
disorders. 
 
 
 
 
 
 
 
321 
 
 
 
 
 
 
 
250 571 USA 100,00% cervical pap smear Y 
age, insurance, 
service 
connection, 
and primary 
care and 
women’s 
clinic visits. 
Y Y 
      
  
      colorectal 
Fecal occult 
blood, flexible 
sigmoidoscopy, 
colonscopy 
      
            breast mammography       
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Yen, 2014 
(47) ⁠ 
clinical 
records 
2 50-69 
delusional 
disorders, 
affective 
disorders, 
schizophrenia, 
childhood-onset 
mental disorder, 
senile and 
presenile mental 
disorders, other 
organic and 
nonorganic 
mental disorders 
 
 
 
 
 
 
13089 
 
 
 
 
 
 
4154 17 243 Taiwan 100% breast mammography N  Y Y 
46studies 
(47 
publications) 
20 
DSM/ICD  
13  scale  
10 clinical 
records 
3 mixed 
 
7  1 year, 
11  2 
years, 
6  3 
years,  
9  4 years 
and more, 
6 mixed, 
6 
lifetime, 
1 NA 
 
 
Range 
18-79  
14 depression, 
6 schizophrenia, 
14 mixed with 
specific 
diagnoses,  
12 mixed without 
specific 
diagnosis 
 
 
 
 
 
501 
559 
 
 
 
4 216 
280 
4 717 
839 
25 USA, 
3 UK, 
1 Taiwan, 
1 Hong 
Kong, 
5 Canada, 
1 EU, 
2 Denmark,1 
Sweden, 
2 Israel, 
1Japan, 
3 Australia,  
1 
USA/Canada 
35 Only 
women, 
2 only 
men  
9 mixed  
12 breast 
only, 
6 cervical 
only, 
2 prostate 
only, 
26 mixed 
11 
Mammography, 
1 breast 
examination, 
6 pap smear, 
2 PSA, 
25 mixed, 
1 NA  
31 
Adjusted, 
15 non 
adjusted  
 
37 with 
association 
measure, 
9 without 
association 
measure 
34 with 
prevalence 
measure, 
12 without 
prevalence 
measure 
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Supplementary table 2. Quality of included studies according to Newcastle-Ottawa Scale.  
 
Study Selection Comparability Outcome Total 
 Representativeness 
of the exposed 
cohort  
Selection 
of the 
non 
exposed 
cohort 
Ascertainment 
of exposure 
Demonstration 
that outcome of 
interest was not 
present at start 
of study 
Comparability 
of cohorts on 
the basis of 
the design or 
analysis 
Assessment 
of outcome 
Was 
follow-up 
long 
enough 
for 
outcomes 
to occur 
Adequacy 
of follow 
up of 
cohorts 
 
Abrams, 2012 (1) * * * - ** * * - 7 
Aggarwal, 2008 
(2) ⁠⁠⁠ 
* * * * ** * * * 9 
Blackwell, 2008 
(3) 
* * - * ** * * - 7 
Carney, 2006 
(4) ⁠ 
* * * * ** * * * 9 
Chochinov, 2009 
(5) 
 
* * * * ** * * - 8 
Domino, 2014 
(6) 
* * * * * * * - 7 
Druss, 2002 
(7) ⁠ 
* * * - * * * - 6 
Druss, 2008 
(8) 
* * * - * * * - 6 
Eriksson, 2019(9) * * * * * * * * 8 
Folsom, 2002(10) * - * * - * * - 5 
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Study Selection Comparability Outcome Total 
 Representativeness 
of the exposed 
cohort  
Selection 
of the 
non 
exposed 
cohort 
Ascertainment 
of exposure 
Demonstration 
that outcome of 
interest was not 
present at start 
of study 
Comparability 
of cohorts on 
the basis of 
the design or 
analysis 
Assessment 
of outcome 
Was 
follow-up 
long 
enough 
for 
outcomes 
to occur 
Adequacy 
of follow 
up of 
cohorts 
 
 
Fujiwara AND Inagaki, 2017, 
2018 
(11, 12)  
⁠⁠ 
* - * - - * - - 3 
Gal,2014 
(13) ⁠ 
* * * - * * * * 7 
Green, 2000 
(14) ⁠ 
* - - * ** * - * 6 
Harder, 2018 
(15) ⁠ 
* * * * ** * * - 8 
Holden, 2015 (16) * - - * - * * - 4 
Iezzoni, 2001 
⁠(17) ⁠ 
* - * * * * * * 7 
Jensen, 2016 (18) * * * * ** * * * 9 
Kaida, 2008 
(19) ⁠ 
* - * - ** * - - 5 
Katz,2018 (20) 
* * * * ** * * * 9 
Kempe, 2013 
(21) 
* * * * ** * * * 9 
Koroukian, 2012 
(22) ⁠ 
* * * * ** * * * 9 
Kotwal, 2012(23) 
* - - * ** - * - 5 
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Study Selection Comparability Outcome Total 
 Representativeness 
of the exposed 
cohort  
Selection 
of the 
non 
exposed 
cohort 
Ascertainment 
of exposure 
Demonstration 
that outcome of 
interest was not 
present at start 
of study 
Comparability 
of cohorts on 
the basis of 
the design or 
analysis 
Assessment 
of outcome 
Was 
follow-up 
long 
enough 
for 
outcomes 
to occur 
Adequacy 
of follow 
up of 
cohorts 
 
Lasser, 2003 
(24) 
* - * * - * * * 6 
Lindamer, 2003 
(25) ⁠ 
- - * * - * * * 5 
Lindamer, 2006(26) 
- - * * - * * * 5 
Long, 1998 
(27) ⁠ 
* - * * - * - * 4 
Ludman, 2010 
(28) 
* * - * ** * - * 7 
Martens, 2009 
(29) ⁠ 
* * * * ** * * - 8 
Masterson, 2010 
(30) 
* - - * ** * - * 6 
Mo, 2014 
(31) ⁠ 
* - * * - * - * 5 
Olesen, 2012 
(32) ⁠⁠ 
* - * * * * * * 7 
Owen, 2002 
(33) ⁠ 
* - * * - * * * 6 
Patten, 2009 
(34) ⁠ 
* * * * ** * * - 8 
Peytremann-Bridevaux, 2008 
(35) ⁠ 
* * * * ** * * - 8 
Pirraglia, 2004 
(36) 
* * - * ** - * * 7 
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Study Selection Comparability Outcome Total 
 Representativeness 
of the exposed 
cohort  
Selection 
of the 
non 
exposed 
cohort 
Ascertainment 
of exposure 
Demonstration 
that outcome of 
interest was not 
present at start 
of study 
Comparability 
of cohorts on 
the basis of 
the design or 
analysis 
Assessment 
of outcome 
Was 
follow-up 
long 
enough 
for 
outcomes 
to occur 
Adequacy 
of follow 
up of 
cohorts 
 
Salsberry, 2005 
(37) ⁠ 
* - * * - * * * 6 
Stecker, 2007 
(38) ⁠ 
* * * - - * * * 6 
Thomas, 2018 
(39) ⁠ 
* - * * - * * * 6 
Tuesley, 2018 (40) 
 
* * * * ** * * * 9 
Vigod, 2011(41) 
 
* * * * ** * * * 9 
Werneke, 2006 
(42) 
* * * * ** * * - 8 
Weitlauf, 2013 
(43) ⁠ 
* * * * ** * - - 7 
Woodhead, 2016 
(44) 
* * * * ** * * - 8 
Xiong, 2008 
(45) ⁠ 
* - * - - - * * 4 
Yee, 2011 (46) 
 
* * * * ** * * * 9 
Yen, 2014 
(47) ⁠ 
* * * - - * * * 6 
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Supplementary table 3. Excluded studies after full text assessment, with reason. 
Author, year Reason for exclusion 
Altman, 2016 (48)⁠ no cancer screening 
Andrykowski, 2014 (49) no cancer screening 
Bagur et al., 2015 (50)⁠ no cancer screening 
Bergerot  2016 (51) no cancer screening 
Bergerot, 2018 (52) no cancer screening 
Bhattacharya, 2016 (53) no cancer screening 
Dauchy, 2013 (54) no cancer screening 
De la Cruz, 2014 (55)  no cancer screening 
De la Garza, 2015 (56)  no cancer screening 
Del Fabbro, 2015 (57) no cancer screening 
Dixon, 2017 (58) no cancer screening 
El-Zorkany, 2016 (59) no cancer screening 
Esser, 2018 (60) no cancer screening 
Fatiregun, 2016 (61) no cancer screening 
Goel, 2003 (62) no cancer screening 
Grassi, 2018 (63) no cancer screening 
Hahn, 2017 (64) no cancer screening 
Hallet, 2018 (65) ⁠ no cancer screening 
Hartung, 2017 (66) no cancer screening 
Hirata, 2016 (67) no cancer screening 
Husson, 2015 (68) ⁠ no cancer screening 
Ito, 2013 (69) no cancer screening 
Jones, 2014 (70)⁠ no cancer screening 
Kang, 2014 (71) ⁠ no cancer screening 
Kim, 2019 (72) No cancer screening 
Kimmel, (73) no cancer screening 
Kisely, 2016(74)⁠ no cancer screening 
Klein, 2017 (75) no cancer screening 
Ko, 2018 (76) ⁠ no cancer screening 
Konstantakopoulos, 2013 (77) no cancer screening 
Lemogne, 2012 (78) no cancer screening 
Li, 2016 (79) no cancer screening 
Lotfi-Jam, 2013 (80) no cancer screening 
Ma, 2013 (81) no cancer screening 
Malalur, 2016 (82) no cancer screening 
Maske, 2016 (83) no cancer screening 
Meiser, 2016 (84) ⁠ no cancer screening 
Mertz 2017 (85) no cancer screening 
Meyer, 2015  (86) no cancer screening 
Millman, 2018 (87) no cancer screening 
Osório, 2015 (88) no cancer screening 
Pan, 2013 (89) no cancer screening 
Panagiotou, 2014 (90) no cancer screening 
Park, 2017 (91)  no cancer screening 
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Author, year Reason for exclusion 
Parrino, 2017 (92) no cancer screening 
Randhawa, 2017 (93) no cancer screening 
Recklitis, 2017 (94) no cancer screening 
Rhondali, 2014 (95) no cancer screening 
Rhondali, 2015 (96) no cancer screening 
Riedl, 2018 (97) no cancer screening 
Saracino, 2017 (98) no cancer screening 
Schaeffeler, 2018 (99) no cancer screening 
Schellekens, 2016 (100) no cancer screening 
Scherber, 2016 (101) no cancer screening 
Shimizu, 2012 (102) no cancer screening 
Shippee, 2017 (103) no cancer screening 
Sitaram, 2014 (104) ⁠ no cancer screening 
⁠Song, 2013 (105) no cancer screening 
Stadelmaier, 2017 (106)⁠ no cancer screening 
Trosman, 2017 (107) no cancer screening 
Tsai, 2014 (108) no cancer screening 
Underwood, 2015 (109) no cancer screening 
Valdes-Stauber, 2013⁠ (110) no cancer screening 
Wagner, 2017 (111)⁠ no cancer screening 
Walming, 2018 (112) no cancer screening 
⁠Watkins, 2015 (113) no cancer screening 
Xu, 2013 (114) no cancer screening 
Zhao, 2014 (115) no cancer screening 
Agay, 2017 (116) no data available 
Aggarwal, 2010 (117) ⁠ no data available 
Andreassen, 2019 (118) no data available 
Baughman, 2016 (119) no data available 
Bires, 2016 (120) no data available 
Burke, 2017(121) ⁠ no data available 
Caruso, 2012 (122) no data available 
Chen 2018 (123) no data available 
Fields, 2017 (124) no data available 
Gross, 2018 (125) no data available 
Halbert, 2016 (126) no data available 
Irwin, 2016 (127) no data available 
Kelly, 2014 (128) ⁠ no data available 
Kronman, 2012 (129) no data available 
Lin, 2010 (130) no data available 
McLay, 2017 (131) no data available 
Montagna, 2019 (132) no data available 
Rashid, 2015 (133) ⁠ no data available 
Sabia, 2016 (134) no data available 
Uemura, 2014 (135) no data available 
Kobayashi, 2018 (136) no mental illness 
Leiferman, 2006 
(137) 
no mental illness 
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Author, year Reason for exclusion 
Schwarz, 2003 
(138) ⁠ 
no mental illness 
Sullivan, 2003 (139) no mental illness 
Thorpe, 2006 
(140) ⁠ 
no mental illness 
Xiang, 2015 (141) no mental illness 
Constantinou, 2016 (142) no valid diagnosis (self-report) 
Kearns. 2018  (143) no valid diagnosis (self-report) 
Massetti, 2017 (144) no valid diagnosis (self-report) 
Rockson, 2016 (145) no valid diagnosis (self-report) 
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Country/region and Mental 
illness 
Cancer Publications/samples Prevalence Heterogeneity Subgroup comparison between 
schizophrenia and mood 
disorders 
Schizophrenia spectrum 
disorders 
Colorectal cancer 3/3 27.4% (17.3-40.4) 79.04%  
Prostate cancer 
Any mental illness Prostate cancer 5/11 48.2% (31.3-65.5) 99.56%  
Asia Prostate cancer 1 /1 20.8% (16.1-26.4) NA <0.001 
Israel Prostate cancer 1/1 26.2% (25.3-27.1) NA  
USA Prostate cancer 3/9 54.9% (42-67.2) 98.24%  
      
Mood disorders Prostate cancer 1/2 49.4% (35.5-63.6) NA <0.001 
Schizophrenia spectrum 
disorders 
Prostate cancer 1/1 26.2% (25.3-27.1) NA  
 
Country/region Publications/samples OR (95%CI)*  p value I2 Subgroup difference across different regions p value 
Cervical cancer 
USA 3/5 1.015(0.707-1.457) 0.935 97.66% 0.089 
Canada 1 / 1 0.700(0.652-0.752) <0.001 NA  
Europe 3/4 0.562(0.351-0.899) 0.016 99.08%  
 
Mood disorders 
 
Any cancer 
Europe 5/7 0.948(0.875-1.028) 0.195 88.47% 0.012 
USA* 15/33 0.850(0.752-0.962) 0.010 99.13%  
Israel 1 / 1 0.767(0.691-0.851) <0.001 NA  
Canada* 4/7 0.761(0.510-1.136) 0.181 85.70%  
Australia 1 / 1 0.630(0.419-0.947) 0.026 NA  
Breast cancer 
Canada* 3/3 1.205(0.594-2.447) 0.605 40.22% 0.215 
Europe 3/3 0.862(0.766-0.969) 0.013 27.88%  
Israel 1 / 1 0.767(0.691-0.851) <0.001 NA  
USA* 12/17 0.733(0.618-0.869) <0.001 98.57%  
Cervical cancer 
Europe 3/3 0.964(0.904-1.028) 0.266 81.24% 0.079 
USA* 8/11 0.943(0.794-1.120) 0.505 97.81%  
Australia 1 / 1 0.630(0.419-0.947) 0.026 NA  
Canada* 4/4 0.629(0.385-1.028) 0.065 92.06%  
Colorectal cancer 
Europe 1 / 1 1.300(1.095-1.543) 0.003 NA 0.354 
USA 4/4 1.157(0.970-1.381) 0.106 97.50%  
#USA and Canada have been considered separately given the difference in health-care system 
* Blackwell1 provided data from both Canada and USA 
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